TD Cowen analyst Charles Rhyee raised the firm’s price target on McKesson (MCK) to $651 from $642 and keeps a Buy rating on the shares. The firm said results were strong across all segements and find strong F2Q performance in US Pharma, as well as midpoint of guide implying segment EBIT acceleration in FY25, encouraging.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCK: